The accurate measurement of human epidermal growth factor type 2 (HER2) gene expression can assist physicians with treatment decisions for patients with cancers in tissues such as breast, said Response Genetics.
Kathleen Danenberg, president and CEO of Response Genetics, said: “We are extremely pleased to be working with Roche to help make personalized medicine a reality for cancer patients. This agreement strengthens our long relationship with Roche and fulfills a promise we made during our initial public offering to license our intellectual property while protecting our intellectual capital freedom.”